Replies to post #175079 on Biotech Values

[goodJohnhunting]

Dew,

I guess the rise in SGMO has answered your question. I.E zinc finger platform..

All the best,
John

[Bio_pete]

Are any non-private biotechs focused on CRISPR technology?

[genisi]

Does Crispr make RNAi and zinc-finger platform companies less valuable?

Crispr technology does and will make a big change in the academic research world and should become a major tool for genome editing, but I don't think that it makes companies that used other commercially available platforms such as zinc-fingers or TALEns less valuable, not at this time yet. Crispr is considered easier and is obviously faster but each method has restrictions and carries the risk for off-target effects and Crisper has to be further evaluated.

[jq1234]

I don't think Crispr has much impact on RNAi, at least not in foreseeable future as it is entirely different approach. I agree with genisi on the hurdle ahead of Crispr for clinical impact. Think where RNAi was 10 years ago, it would take at least that long if not longer for Crisp to have similar impact RNAi has today IMO.